REG - Fortis Frontier PLC - Transaction in Own Shares and Total Voting Rights

Fortis FrontierAnnouncement

Mon 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260112:nRSL5737Oa&default-theme=true

RNS Number : 5737O  Fortis Frontier PLC  12 January 2026

 

Fortis Frontier PLC

("Fortis Frontier" or the "Company")

 

Transaction in Own Shares and Total Voting Rights

 

Fortis Frontier plc (AIM: FORF), an AIM Rule 15 cash shell (formerly
MyHealthChecked PLC), announces that on 9 January 2026, pursuant to the
authority approved by shareholders at the Company's Annual General Meeting of
31 July 2025, the Company purchased 100,000 ordinary shares of 1.5 pence each
("Ordinary Shares") for cancellation at a price of 8 pence per share.

 

In addition, 105 Ordinary Shares held in treasury since the share
consolidation in May 2023 will also be cancelled.

 

Summary of Trades

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No
596/2014 (which forms part of domestic law pursuant to the European Union
(Withdrawal) Act 2018), details of the purchase of its own ordinary shares by
Fortis Frontier plc which were all executed through the Company's broker,
Dowgate Capital, are set out below:

 

 Date of Purchase                                        9 January 2026
 Number of ordinary shares purchased/aggregated volume   100,000
 Highest price paid per ordinary share                   8p
 Lowest price paid per ordinary shares                   8p
 Volume weighted average price paid per ordinary shares  8p
 Trading Venue                                           London Stock Exchange

 

Total Voting Rights

An application to cancel the repurchased shares will be made as soon as
practicable, pending which the shares will be held in treasury. Following
settlement of the above purchases and cancellation of the Ordinary Shares held
in treasury, the Company's total number of ordinary shares in issue shall be
51,935,827.

 

The total voting rights figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.

 

For further information contact:

 

 Fortis Frontier PLC                                                                www.fortisfrontierplc-ir.com (http://www.fortisfrontierplc-ir.com)
 Adam Reynolds, Executive Chairman                                                  via Walbrook PR

 SPARK Advisory Partners Limited (NOMAD)                                            Tel: +44 (0)20 3368 3550
 Neil Baldwin / Dillon Wall

 Dowgate Capital Limited (Broker)                          Tel: +44 (0)20 3903 7715
 David Poutney / Russell Cook

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or Fortis fortisfrontier@walbrookpr.com
                                   (mailto:Fortis%20fortisfrontier@walbrookpr.com)
 Paul McManus / Alice Woodings                             Mob: +44 (0)7980 541 893 / +44(0)7407 804 654

 

About Fortis Frontier PLC

On 10 November 2025 MyHealthChecked PLC completed the disposal of its trading
subsidiary, Concepta Diagnostics Limited, becoming an AIM Rule 15 Cash Shell,
as defined in the AIM Rules for Companies. On the same day the Company changed
its name to Fortis Frontier PLC. The Board is now carefully considering the
strategic options available to it in order to maximise shareholder value.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSGPUCCGUPQGAP



            Copyright 2019 Regulatory News Service, all rights reserved